Clinical Trial Update: Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for idelalisib in relapsed diffuse large B-cell lymphoma has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Idelalisib (idelalisib)

Snippet

Sponsor: Nordic Lymphoma Group | Conditions: Diffuse Large B Cell Lymphoma | Phase 2 | Status: COMPLETED